Abstract | BACKGROUND: OBJECTIVE: METHODS: A total of 21 mastocytosis patients-4 women (19%) and 17 men (81%) with a median age of 50 years (range, 29-74 years)-with Hymenoptera sting anaphylaxis who were treated with VIT and followed for a median of 52 months (range, 2-250 months) were studied. RESULTS: In 18 of 21 patients-16 of them lacking skin involvement- anaphylaxis was the presenting symptom. Six patients (29%) experienced adverse reactions during VIT, 3 during initiation and 3 during maintenance. Twelve patients (57%) were resting while undergoing VIT; 9 (75%) presented local reactions and 3 (25%) systemic reactions, 1 of which required intubation. The Hymenoptera specific IgE decreased from 4.15 kU/L (range, 0.44-100 kU/L) before immunotherapy to 1.2 kU/L (range, 0.34-69.4 kU/L) after 4 years (P < .003). CONCLUSION: Venom immunotherapy is effective to treat IgE-mediated Hymenoptera anaphylaxis in patients with mastocytosis. Its use is recommended despite a relatively high risk of adverse reactions during the build-up phase because it provides protection from anaphylaxis in around 3/4 of the patients.
|
Authors | David González de Olano, Iván Alvarez-Twose, María I Esteban-López, Laura Sánchez-Muñoz, María D Alonso Díaz de Durana, Arantza Vega, Andres García-Montero, Eloina González-Mancebo, Teresa Belver, María D Herrero-Gil, Montserrat Fernández-Rivas, Alberto Orfao, Belén de la Hoz, Mariana C Castells, Luis Escribano |
Journal | The Journal of allergy and clinical immunology
(J Allergy Clin Immunol)
Vol. 121
Issue 2
Pg. 519-26
(Feb 2008)
ISSN: 1097-6825 [Electronic] United States |
PMID | 18177694
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Arthropod Venoms
- Epitopes
- Immunoglobulin E
|
Topics |
- Adult
- Aged
- Anaphylaxis
(chemically induced, complications)
- Animals
- Arthropod Venoms
- Cohort Studies
- Epitopes
- Female
- Humans
- Hymenoptera
(immunology)
- Immunoglobulin E
(blood)
- Immunotherapy
(adverse effects)
- Insect Bites and Stings
(complications)
- Male
- Mastocytosis, Systemic
(complications, therapy)
- Middle Aged
- Recurrence
- Treatment Outcome
|